FDA approves Novartis drug to treat pancreatic neuroendocrine tumors

Friday, May 6, 2011 12:34 PM

The FDA has approved the Novartis drug Afinitor(everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. 

Afinitor underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove efficacy in patients with pancreatic neuroendocrine tumors.  Afinitor is designed to attack specific proteins that are necessary for the growth of cancer cells.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs